Zura Bio ZURA 深 沪
交易中 11-09 09:52:41 美东时间
1.145
-2.945
-72.00%
华盛通- 最 高1.265
- 今 开1.25
- 成交量 1688.55万股
- 最 低 1.11
- 昨 收 4.09
- 总市值 1.10亿
- 52周最高 7.44
- 市盈率 静 --
- 换手率 17.53%
- 52周最低 1.11
- 委 比 52.38%
- 总股本 9632.54万
- 历史最高 37.55
- 量 比 354.61
- 振 幅 3.79%
- 历史最低 0.97
- 每 手 1
- 风险率 0.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Zura Bio Says Phase 2 TibuSHIELD Study Of Tibulizumab In Hidradenitis Suppurativa Missed Primary And Key Secondary Endpoints
Study did not meet primary endpoint of percentage change from baseline in total abscess and inflammatory nodule (AN) count at Week 16 Key secondary endpoints, including HiSCR50 and HiSCR75, were not met Both doses of tibulizumab were well tolerated; observed safety was consistent with established sa...
今天 20:18
Zura Bio Files Prospectus To Offer Up To $700M Of Securities
Zura Bio Files Prospectus To Offer Up To $700M Of Securities
10-28 05:19
Zura Bio Highlights Q3 Results and Tibulizumab Progress
The latest update is out from Zura Bio ( ($ZURA) ). On October 27, 2026, Zura B...
10-27 19:57
Zura Bio Q3 EPS $(0.20), Inline
Zura Bio (NASDAQ:ZURA) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 4.76 percent increase over losses of $(0.21) per share from the same period last year.
10-27 19:33
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were lower, with the Dow Jones index falling around 1% on Wednesday. Shares of BKV Corp (NYSE:BKV) rose sharply after the company announced that a subsidiary executed into an equipment supply contract. BKV shares jumped 9.2% to $24.08 on Wednesday. Here are some other big stocks recordin...
10-07 22:08
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20
Guggenheim analyst Yatin Suneja maintains Zura Bio (NASDAQ:ZURA) with a Buy and raises the price target from $15 to $20.
08-12 20:28
William Blair Initiates Coverage On Zura Bio with Outperform Rating
William Blair analyst Matt Phipps initiates coverage on Zura Bio (NASDAQ:ZURA) with a Outperform rating.
07-09 02:54
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy
On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, citing the potential of its lead candidate, tibulizumab, to deliver differentiated efficacy across severe autoimmune diseases. Analyst Matt Phipps said the investment thesis centers on tibuliz...
07-09 01:24
